Belviq lorcaserin: Phase II started

Arena and Eisai began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 10 mg oral lorcaserin given once daily or twice daily for 12 weeks in about 600 active smokers receiving smoki...